Introduction
============

Endogenous compounds are often used as a basis, or structural component, of pharmacological preparations. For example indirubin is the active ingredient of Danggui Longhui Wan, a mixture of plants that is used in traditional Chinese medicine to treat chronic diseases ([@b41-btt-1-151]) and also individual Chinese medicinal herbs *Isatis indigotica* and *Strobilanthes cusia* ([@b67-btt-1-151]). Indirubin derivatives are potent inhibitors of cyclin dependent kinases and some other pharmacologically important kinases. Indirubin may be formed during dimerization of isatin ([Figure 1](#f1-btt-1-151){ref-type="fig"}), another biologically active compound, which attracts much interest of pharmacologists. Isatin (indoledione 2, 3) is an endogenous indole found in the mammalian brain, peripheral tissues and body fluids (see for review [@b77-btt-1-151]; [@b32-btt-1-151]; [@b79-btt-1-151]; [@b80-btt-1-151]). The isatin moiety is also present in a range of compounds which can act as inhibitors of apoptosis ([@b59-btt-1-151]; [@b14-btt-1-151]), anticonvulsants ([@b118-btt-1-151]), and other antiviral ([@b105-btt-1-151]; [@b92-btt-1-151]), anti-bacterial and anti-fungal ([@b18-btt-1-151]) agents. It is possible that drugs containing the isatin moiety, may compete with endogenous isatin, and the latter can influence their therapeutic effect. Consequently, analysis of the isatin content of the body, its metabolic routes, and its interactions may not only be of importance for understanding more about the function of this endogenous regulator, but also for understanding its possible role as a functional agonist/antagonist of drugs.

In this review we discuss the wide range of biological targets that are known to be sensitive to isatin and its analogues and the evidence that endogenous isatin may affect their responsivity.

Metabolism
==========

Isatin was originally identified as one component of the endogenous monoamine oxidase (MAO) inhibitory activity, tribulin ([@b32-btt-1-151]). The isatin concentration in blood can exceed 1 μM ([@b68-btt-1-151]; [@b73-btt-1-151]; [@b46-btt-1-151]). Based on tissue isatin ([@b122-btt-1-151]) and water ([@b96-btt-1-151]) content calculations, basal isatin tissue concentrations are different in various organs ([Table 1](#t1-btt-1-151){ref-type="table"}). Highest concentrations in the brain are in hippocampus, cerebellum and striatum (1--1.3 μM), whereas in peripheral organs the highest concentrations are in seminal vesicles and vas deferens: 47.4--79 μM. In the heart the maximal basal concentration approaches to 3 μM. In other rat organs basal isatin concentrations vary from 0.3 μM (spleen) to 1.5 μM (liver). In the rat, stress causes the 2--3 fold increase of isatin content in the brain and heart ([@b26-btt-1-151]), 2.5--6 fold increase of isatin output in urine ([@b113-btt-1-151]), and its concentration in serum reaches 2.9 ± 0.29 μM ([@b46-btt-1-151]). This suggests that under certain conditions isatin concentrations may be as high as 10 μM and even more (if we take into consideration exceptionally high concentrations in seminal vesicles and vas deferens).

Although the pathways of endogenous isatin formation (see [Figure 1](#f1-btt-1-151){ref-type="fig"}) still require better experimental support there is in vitro evidence that isatin can be formed from indole, typically produced by tryptophan catabolism in the gut, and that this involves microsomal cytochrome P450 ([@b31-btt-1-151]). Besides excretion with urine, the catabolic pathways of isatin include further, possibly spontaneous, oxidation and dimerization yielding the indigoid pigments, indigo and indirubin ([@b77-btt-1-151]; [@b31-btt-1-151]), hydrogen peroxide-dependent conversion into anthranilic acid ([@b79-btt-1-151]) and NADPH-dependent reduction to 3-hydroxy-2-oxoindole ([@b117-btt-1-151]). All these compounds have been found in urine ([@b117-btt-1-151]; [@b79-btt-1-151]). However, it remains unclear whether indigoid formation precedes urinary excretion and aerobic transformation of the urinary components. Interestingly, during in vitro oxidation of indole by cytochrome P450 enzymes, isatin was an intermediate, which was then transformed into the indigoid pigment major end products (Gilliam et al 2000).

The study of isatin content in conventional and germ-free rats has shown that at least for basal isatin, urinary but not tissue levels are largely produced by the gut flora. Urinary isatin levels in germ free rats are 50 times lower than in samples from conventional rats, but both have similar concentrations in tissues ([@b99-btt-1-151]). This suggests that gut flora do have an important role in the production of urinary isatin, at least in the rat.

Biological targets
==================

Distribution of isatin-binding sites
------------------------------------

Several lines of experimental evidence suggest the existence of multiple binding sites for isatin in the brain and other tissues. \[^3^H\]isatin imaging in situ has shown the pattern of isatin-binding sites in different parts of the rat brain ([@b22-btt-1-151]). The highest labeling was found in hypothalamic nuclei, in the cortex, the hippocampus, and the cerebellum. Administration of the MAO inhibitor, pargyline, to rats caused some reduction, but did not abolish the \[^3^H\]isatin-binding ([@b22-btt-1-151]). This suggests that MAO is one of the isatin-binding sites in situ. Indeed, this has been demonstrated using high-resolution crystal structures of recombinant MAO B with isatin and its tight binding led to an improved crystal quality ([@b6-btt-1-151]). Other putative isatin binding sites in the rat brain include atrial natriuretic peptide (ANP) and C-type natriuretic peptide, which inhibit \[^3^H\]isatin-binding to rat brain sections and isolated membrane fractions ([@b78-btt-1-151]). These results suggest that some \[^3^H\]isatin-binding in the brain may be to the natriuretic peptide receptors (NPR) ([@b78-btt-1-151]). Using an optical biosensor technique isatin-binding sites have been demonstrated in both particulate and soluble fractions of the brain and peripheral rat tissues ([@b49-btt-1-151]; [@b79-btt-1-151]). In the brain isatin-binding predominated in the membrane fraction, whereas in the kidneys the highest binding was observed in the soluble fractions. The distribution of isatin-binding sites in the particulate fraction reduced in the following order: brainstem \> brain hemispheres = cerebellum \> heart \> kidneys \> liver. In the soluble fraction there was a different rank of isatin-binding.

There are biological targets that specifically bind isatin and also those sensitive to inhibition by physiologically relevant concentrations of isatin. The former group includes MAO, the cytosolic enzymes glycerol-3-phosphate dehydrogenase ([@b8-btt-1-151]), glyceraldehyde-3-phosphate dehydrogenase ([@b89-btt-1-151], [@b75-btt-1-151]), pyruvate kinase ([@b7-btt-1-151]), and ubiquitin (Buneeva et al prepared for publication). Other isatin binding proteins detected in both soluble and particulate fractions of various tissues using optical biosensor technique ([@b49-btt-1-151]) require detailed investigation and identification (Buneeva et al in preparation).

### Isatin-binding proteins

Pyruvate kinase (PK; EC 2.7.1.40) is an important glycolytic enzyme, which catalyses the reaction of a phosphoryl group transfer from phosphoenolpyruvate to ADP in the reaction of substrate phosphorylation: Phosphoenolpyruvate + ADP → (Enol)pyruvate + ATP. Rabbit muscle pyruvate kinase (this isoform is also present in the brain ([@b116-btt-1-151]; [@b126-btt-1-151])) did bind isatin and the K~d~ value of 10 μM was at the upper physiological range of isatin concentrations ([@b7-btt-1-151]). This interaction appeared to be specific as the other enzyme of this class, creatine kinase (EC 2.7.3.2) did not exhibit concentration dependent binding of \[^3^H\]isatin ([@b7-btt-1-151]). Pyruvate kinase interaction with isatin was sensitive to inhibition by ATP (IC~50~ of 25 μM) and by a neuroprotective preparation, deprenyl (IC~50~ of 5 μM). Although the biological role of this interaction is not fully understood, it may be that this phenomenon underlies some non-glycolytic functions of this enzyme ([@b7-btt-1-151]). Indeed certain evidence exists that pyruvate kinase is the factor of regulation of cytoskeletal proteins ([@b120-btt-1-151]; [@b55-btt-1-151]), it is also involved in resistance of glial cells to hypoxia ([@b101-btt-1-151]).

### Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH; EC 1.2.1.12) is a classical glycolytic enzyme, exhibiting diverse nonglycolytic functions in dependence of its subcellular localization. GAPDH specifically interacts with different RNAs in vivo and in vitro ([@b85-btt-1-151]; [@b26-btt-1-151]; [@b61-btt-1-151]; [@b128-btt-1-151]; [@b30-btt-1-151]) and may cleave some of them ([@b30-btt-1-151]). Overexpression of GAPDH and its subsequent nuclear translocation are implicated in the initiation of one or more apoptotic cascades and also in the aetiology of some neurological diseases ([@b109-btt-1-151]; [@b3-btt-1-151]). The translocation of GAPDH into the nucleus can be an important event leading to apoptosis ([@b109-btt-1-151]; [@b3-btt-1-151]), especially in neuronal cells.

There is increasing evidence that GAPDH may serve as a target for small-molecule anti-apoptotic compounds slowing/preventing progression of neurodegenerative disorders ([@b50-btt-1-151]; [@b3-btt-1-151]). GAPDH is thus a promising target for various neuroprotective drugs and good evidence now exists that the binding of deprenyl (initially introduced as a mechanism-based MAO B inhibitor) and other propargylamines to GAPDH is primarily responsible for the neuroprotective and antiapoptotic effects of these substances ([@b11-btt-1-151]; [@b56-btt-1-151]; [@b72-btt-1-151]; [@b109-btt-1-151]; [@b3-btt-1-151]).

Besides these pharmacological substances GAPDH can also bind isatin ([@b75-btt-1-151]) with K~d~ values (of 12 and 3.1 μM, determined by two independent methods respectively), which are within the upper physiological limit of isatin concentrations. Such interaction was relatively specific because another oligomeric cytosolic NAD-dependent enzyme, lactate dehydrogenase, did not bind to the immobilized isatin analogue ([@b75-btt-1-151]). Binding of GAPDH to isatin only weakly influenced the glycolytic activity of this enzyme but inhibited GAPDH-mediated cleavage of *E. coli* tRNA.

### Glycerol-3-phosphate dehydorgenase (GPDH)

Highly purified rabbit muscle GPDH effectively binds to the isatin analogue immobilised on the cuvette of IAsys optical biosensor ([@b8-btt-1-151]). Replacement of the cuvette medium for washing buffer did not cause total dissociation of GPDH-isatin complexes. This suggests involvement of several types of enzyme-isatin interaction including tight binding. Although 10 μM and 100 μM concentrations of isatin caused different effects on GPDH activity: the former significantly increased apparent K~m~ for NAD, whereas the latter decreased apparent V~max~ and increased K~m~, -- possible biological significance of this regulation remains unclear.

### Ubiquitin

Ubiquitin is a highly conserved 8 kDa protein, which is covalently attached to lysine residues of target proteins by the ubiquitin conjugation system. This metabolic pathway is often used for the selective proteasome degradation of many short-lived proteins in eukaryotic cells. The ubiquitin-mediated degradation of regulatory proteins plays important roles in the control of numerous processes, including cell-cycle progression, signal transduction, transcriptional regulation, receptor down-regulation, and endocytosis ([@b39-btt-1-151]). The ubiquitin system is involved into the immune response, development, programmed cell death, and abnormalities in ubiquitin-mediated processes may be a cause for development of various pathological conditions, including malignant transformation ([@b38-btt-1-151]; [@b40-btt-1-151]), systemic lupus erythematosus (Jury et al 2003) and other autoimmune diseases ([@b52-btt-1-151]), Parkinson's disease ([@b23-btt-1-151], [@b9-btt-1-151]), etc.

We have recently demonstrated that ubiquitin binds to an isatin analogue immobilized at the Biacore cell (Buneeva et al in preparation). Although the K~d~ value of 0.27 mM is rather high, this phenomenon may have implications for ubiquitin interaction with isatin analogues (see below).

Biological targets sensitive to inhibition by isatin
----------------------------------------------------

[Table 2](#t2-btt-1-151){ref-type="table"} summarizes current knowledge of the effects of physiological concentrations of isatin on molecular targets in vitro. The most sensitive in vitro targets for isatin are the ANP signaling system, which includes ANP receptor binding, ANP receptor coupled particulate guanylate cyclase (natriuretic peptide receptor type A, NPR-A) ([@b34-btt-1-151]; [@b81-btt-1-151]; [@b80-btt-1-151]), soluble NO stimulated guanylate cyclase ([@b76-btt-1-151]), and MAO B ([@b79-btt-1-151]). They are sensitive to fluctuations of physiological concentrations of isatin. Although other targets listed in this [Table 1](#t1-btt-1-151){ref-type="table"} exhibit rather low sensitivity to the highest physiological concentration of isatin it is possible that using isatin moiety as a lead structure it would be possible to obtain pharmacologically attractive compounds acting as effective inhibitors of these regulatory systems. There are many examples, when the presence of various substituents in the isatin moiety significantly increased biological activity to particular targets (see below).

### Atrial natriuretic peptide signaling system

The natriuretic peptides are a family of related compounds, including atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). These peptides and their receptors represent an important regulatory system ([@b1-btt-1-151]; [@b94-btt-1-151]), involved not only in the regulation of fluid homeostasis and blood pressure, but also into regulation of emotional behavior (eg, anxiety and arousal) and in altered stress hormone release and autonomic nervous system activation ([@b125-btt-1-151]). Natriuretic peptides interact with three types of membrane receptor. Two of them, natriuretic peptide receptor type A (NPR-A) and natriuretic peptide receptor type B (NPR-B), are transmembrane glycoproteins exhibiting ligand-dependent intrinsic guanylyl cyclase activity ([@b1-btt-1-151]; [@b104-btt-1-151]; [@b83-btt-1-151]; [@b114-btt-1-151]; [@b94-btt-1-151]). ANP and BNP bind preferentially to NPR-A, whereas CNP exhibits much higher affinity for NPR-B. The third receptor, natriuretic peptide receptor type C (NPR-C), lacks the cyclase domain and binds all three peptides. NPRC receptors are coupled to adenylyl cyclase inhibition through inhibitory guanine nucleotide-regulating protein ([@b1-btt-1-151]; [@b104-btt-1-151]; [@b83-btt-1-151]; [@b114-btt-1-151]; [@b94-btt-1-151]).

Isatin inhibited \[^125^I\]ANP binding to guinea pig cerebellar membranes ([@b34-btt-1-151]) and the IC~50~ of 0.4 μM is within the lower limit of the physiological range of isatin concentrations (0.3--1.3 μM). ANP and CNP inhibited \[3H\]isatin-binding to rat brain sections and isolated membrane fractions and the IC~50~ value for the ANP effect (0.2 μM) ([@b78-btt-1-151]) was very close to the corresponding effect of isatin on ANP binding. Isatin also inhibited rat brain particulate guanylyl cyclase activity stimulated by ANP and BNP ([@b81-btt-1-151]). This suggests the involvement of NPR-A. Recently, it has been reported that isatin in situ blocks the effect of ANP on hyperpolarization-activated current in human atrial myocytes involving cyclic GMP signaling ([@b63-btt-1-151]). The latter provides further experimental evidence for isatin interaction with NPR-A. Isatin administration blocked cyclic GMP excretion under conditions of fluid overload, which is known to induce endogenous ANP release ([@b74-btt-1-151]). This provides evidence that isatin can antagonise NPR-A signaling in vivo. Indeed perfusion with 10 μM isatin administration aborted the protective effect of atrial natriuretic peptide administered just prior to reperfusion evaluated by limited infarction in rabbit hearts ([@b127-btt-1-151]). Isatin administration has been shown to block cyclic GMP excretion under conditions of fluid overload, which is known to induce endogenous ANP release ([@b74-btt-1-151]). This provides further evidence that isatin can antagonise NPR-A signaling in vivo.

At high concentrations (100 μM) isatin may also inhibit natriuretic peptide signaling associated with NPR-C ([@b78-btt-1-151]). This is consistent with isatin inhibition of ANP, BNP and CNP-induced behavioral effects ([@b4-btt-1-151], [@b5-btt-1-151]; [@b110-btt-1-151]; [@b90-btt-1-151]), because the three major natriuretic peptides only act in common at one type of natriuretic peptide receptor type C, NPR-C ([@b1-btt-1-151]; [@b104-btt-1-151]; [@b83-btt-1-151]; [@b94-btt-1-151]).

[@b93-btt-1-151] have reported that pretreatment with isatin (100 μg bilaterally) abolished the effect of bremazocine, a κ-opioid receptor agonist, causing enhanced total outflow facility by enhancing levels of natriuretic peptide (ANP, BNP, CNP) in aqueous humor. This is further evidence suggesting that isatin antagonizes natriuretic peptide receptors in situ and in vivo.

### Nitric oxide stimulated soluble guanylate cyclase

Besides membrane bound gualylate cyclase coupled to natriuretic peptide receptors the soluble guanylate cyclase is the other enzyme catalyzing cGMP formation from GTP. The enzyme is activated by NO (formed from L-arginine by nitric oxide synthase) and various NO donors including those employed clinically ([@b65-btt-1-151]; [@b54-btt-1-151]; [@b96-btt-1-151]). The enzyme plays an important role in vasodilation ([@b44-btt-1-151]; [@b43-btt-1-151]). It has been shown that basal activity of the human platelet guanylate cyclase is not sensitive to isatin whereas the NO-stimulated activity is inhibited by low physiological concentrations of isatin (in the 10^--8^ to 10^--6^ M range) ([@b76-btt-1-151]). Subsequent increase of isatin concentration was accompanied by clear decrease of its effect.

The unidirectional regulation of particulate (NPR-A) and soluble guanylate cyclases by different range of isatin concentration is suggested to be important for stress-induced switch in metabolic processes sensitive to cGMP-dependent control ([@b76-btt-1-151]).

### Extracellular signal regulated protein kinase (ERK)

This enzyme existing as ERK1 and ERK2 isoforms is activated via phosphorylation and the activated ERK phosphorylates cytoplasmic, membrane and nuclear substrates required for sequential transition of cell cycle phases (particularly G1/S and G2/M transitions) ([@b13-btt-1-151]). Treatment of cells with 60--100 μM isatin reduced ERK activity and significantly reduced phosphrylation of the EKR2 isoform ([@b10-btt-1-151]).

### Cell cultures

Isatin can induce cell death, including apoptosis in some tumor cells. However, molecular targets responsible for this effect remain unknown. [@b45-btt-1-151] have shown that isatin (50--100 μM) increased apoptosis in dopaminergic neuroblastoma SH-SY5Y cells. At higher isatin concentrations the cells died via necrosis. [@b10-btt-1-151] observed antiproliferative effect of isatin in both tumor (human promyelocytic leukemia HL60 cells, rat adrenal pheochromocytoma PC12 cells, mouse N1E-115 neuroblastoma cells) and normal cells (mouse fibroblast BALB/c3T3 cells, bovine brain capillary BBC cells). The effective concentration, required for a 50% effect was at the upper limits of physiological concentrations or higher (10--50 μM). In both these studies the cells were cultured with low serum concentrations as a source of growth factors and it remains to be determined whether normal and/or tumor cells would be similarly vulnerable.

Isatin (10--100 μM) inhibited nitric oxide production by RAW 264.7 macrophage cells activated by a mixture of lipopolysaccharide (LPS) and interferon γ in a dose dependent manner. It also inhibited production of prostaglandin E2 (PGE2) and tumor necrosis factor (TNF-α) ([@b70-btt-1-151]). The inhibition of NO and PGE2 production in LPS-INF-γ is obviously associated with the isatin effect on expression of inducible nitric oxide synthase and cyclooxygenase-2 (COX-2) respectively, as it has been demonstrated by a Western blot analysis ([@b70-btt-1-151]).

Isatin metabolites and analogues and their effects on biological targets
========================================================================

Isatin and its metabolites are constituents of natural substances and also components of synthetic compounds exhibiting: antiviral activity ([@b67-btt-1-151]), antitumor and antiangiogenic activity ([@b87-btt-1-151]; [@b12-btt-1-151]), antibacterial, antitubercular, antifungal ([@b18-btt-1-151]; [@b87-btt-1-151]), and other activities. Some of them are effective anticonvulsants and anxyolytics ([@b87-btt-1-151]). The specific biological targets responsible for these diverse effects are not all known. However there are several specific targets, which have attracted considerable attention in relation to the regulatory or pharmacological effects of isatin and its metabolites and analogues.

Proteases
---------

Isatin analogues possessing various substituents at R-R\'\'\' and R\'\'\'\'\' (see [Figure 2](#f2-btt-1-151){ref-type="fig"}) were active against SARS coronavirus 3CL protease (belonging to the family of serine proteases), an important target for design of drugs for treatment of a new viral atypical pneumonia, known as severe acute respiratory syndrome (SARS). The IC~50~ values were within the concentration range from 0.95 to 17.50 μM ([@b15-btt-1-151]). The effect of the most active compound tested was highly specific: inhibition of other serine proteases (trypsin, chymotrypsin) and papain (cysteine protease) was observed at much higher concentrations (10 μM^--1^ mM) ([@b15-btt-1-151]).

N-substituted isatin derivatives (but not isatin itself ) inhibited parasitic cysteine proteases identified in trypanosomes (cruzain and rhodesain) and malaria parasites (falcipain-2) ([@b17-btt-1-151]).

[@b123-btt-1-151] synthesized isatin-based inhibitors of human rhinovirus 3C protease, a viral enzyme that is absolutely required for the proteolytic cleavage of viral precursor polyproteins to functional proteins ([@b121-btt-1-151]).

Simple N-substituted isatin analogue, N-carbobenzyloxy isatin, acted as a slow binding inhibitor of chymotrypsin but not of porcine elastase ([@b48-btt-1-151]). N-substituted isatins containing complex substituents effectively inhibited human serine proteases: chymotrypsin, leukocyte elastase and plasmin ([@b102-btt-1-151]).

Caspases
--------

Caspases are a family of cysteine-dependent aspartate-directed proteases. There are at least 14 caspases known to date, which play a significant role in apoptosis and inflammation ([@b29-btt-1-151]; [@b130-btt-1-151]; [@b115-btt-1-151]). Caspases (8 and 9) function as "upstream"-initiators of the proteolytic cascade or "downstream"-effectors (caspases 3, 6, 7) ([@b19-btt-1-151]). Recent studies suggest that caspases are also involved in many other physiological processes such as immunity and cell differentiation, cell cycle, regulatory mechanisms in nervous tissue, etc. ([@b112-btt-1-151]; [@b57-btt-1-151]). Numerous data show that caspases' cascades take part in the dysfunction and death of neurons in neurodegenerative disorders, including Alzheimer's, Parkinson's and Hantington's diseases ([@b29-btt-1-151]; [@b115-btt-1-151]; [@b51-btt-1-151]; [@b71-btt-1-151]; [@b82-btt-1-151]). There is an increasing evidence that caspase substrates serve as molecular targets in the damaging mechanisms in pathogenesis of cardiovascular dysfunctions, autoimmune and autoinflammatory diseases, various forms of cancer, rheumatic, ophthalmologic dysfunctions and many other diseases ([@b36-btt-1-151]; [@b37-btt-1-151]; [@b107-btt-1-151]; [@b38-btt-1-151]; [@b53-btt-1-151]; [@b27-btt-1-151]; [@b97-btt-1-151]; [@b95-btt-1-151]; [@b119-btt-1-151]; [@b103-btt-1-151]; [@b112-btt-1-151]; [@b111-btt-1-151]).

The simple isatin analogue, 5-nitroisatin effectively inhibited caspase-7 (K~i~ 0.29 μM), caspase-3 (K~i~ 0.50 μM), and caspase-6 (K~i~ 1.6 μM) ([@b59-btt-1-151]). SB-281277, a specific isatin sulfonamide inhibitor of caspase-3/-7 inhibited caspase-3 and -7 with a K~i~ of 15 and 47 nM, respectively. This compound exhibited 100-fold greater selectivity for highly homologous caspase-3 and -7 vs all other family members except caspase-9 (K~i~ of 460 nM) ([@b59-btt-1-151]). Isatin sulfonamides, selective caspases 3/7 inhibitors blocked apoptosis in murine bone marrow neutrophils and human chondrocytes ([@b59-btt-1-151]). SB-281277 prevented the ability of bisphosphonate caspase activators (zoledronic acid, clodronate or alendronate) to cause the characteristic changes in nuclear morphology of rabbit osteoclasts associated with apoptosis ([@b2-btt-1-151]).

Pyrrolidine and azetidine isatin also acted as caspase inhibitors and most of them exhibited high inhibitory potency against caspase-3 (IC~50~ of 5--10 nM) and caspase-7 (IC~50~ 15--25 nM).

Kinases
-------

Protein kinases constitute a very large family of potential targets in a variety of diseases. Cyclin-dependent kinases (CDK) are positive regulators of cell cycle progression ([@b84-btt-1-151]). They are key regulators of embryonic development and cancer and several CDK inhibitory drugs are at various stages of clinical trials as antitumor agents ([@b100-btt-1-151]). There is evidence that cyclin-dependent kinases (CDK) are major regulators of T cell immunity and tolerance (see for review [@b98-btt-1-151]; [@b124-btt-1-151]). These enzymes represent novel potential targets for therapy in autoimmune disease and organ transplantation.

There is evidence that indirubin, originating from the dimerization of isatin (see [Figure 1](#f1-btt-1-151){ref-type="fig"}) and its derivatives are potent inhibitors of CDKs1 ([@b41-btt-1-151], [@b58-btt-1-151]). Indirubins exhibit a strong affinity for CDKs (IC~50~ values in the range of 50--100 nM) ([@b41-btt-1-151], [@b58-btt-1-151]). Other kinases (c-Src tyrosine kinase, caseine kinase, insulin receptor tyrosine kinase, cAMP-dependent protein kinase, cGMP-dependent protein kinase, protein kinases C α and β1, c-Raf, MAPK, ERK) exhibited much lower sensitivity (IC~50~ values from 1.5 μM and above) ([@b41-btt-1-151]).

Substituted indirubins, produced by *Escherichia coli*-expressed human P450 2A6 mutants cultivated in the presence of 5-methylindole or 5-methoxyindole inhibited human CDK-1 and -5 with IC~50~ values of 0.4--1.2 μM and glycogen synthase kinase-3α/β ([@b35-btt-1-151]).

Indirubins effectively inhibited glycogen synthase kinase-3β (GSK-3β) with IC~50~ values in the 5--50 nM range ([@b58-btt-1-151]). This kinase is involved in multiple physiological processes, including cell cycle regulation by controlling the levels of cyclin D1 ([@b28-btt-1-151]) and β-catenin ([@b129-btt-1-151]), insulin effect on glycogen synthesis ([@b21-btt-1-151]; [@b108-btt-1-151]), axonal outgrowth ([@b64-btt-1-151]), HIV-1 Tat mediated neurotoxicity ([@b66-btt-1-151]), etc. GSK-3β and CDK5 are responsible for most of the abnormal hyperphosphorylation of the microtubule-binding protein tau observed in the paired helical filaments, which are diagnostic for Alzheimer's disease (AD) ([@b47-btt-1-151]; [@b69-btt-1-151]). Thus indirubins may constitute a lead compound in the study and treatment of neurodegenerative disorders.

The endogenous activity of ERK was significantly decreased by treatment with isatin 5-hydroxyoxindole. The activity was inhibited in a concentration-dependent manner by both endogenous compounds. Concentrations of 60 mM were necessary to obtain significant inhibition with 5-hydroxyoxindole and isatin (20% and 25%, respectively). 5-hydroxyoxindole was more active than isatin in inhibition of ERK2 phosphorylation. These effects appear to be rather selective as both compounds did not influence ERK1 phosphorylation ([@b10-btt-1-151]).

Others
------

Reverse transcriptase, catalyzing the reaction of DNA synthesis on RNA template is considered as a promising target for anti-HIV drugs ([@b25-btt-1-151]; [@b91-btt-1-151]). Aminopyrimidinimino isatin derivatives inhibited replication of HIV type 1 in T4 lymphocytes (CEM cell line) and especially in MT-4 cells, however, their effectiveness was significantly lower than that of the reference standard Nevirapine ([@b106-btt-1-151]). Although in vitro assay revealed that the compounds possessing anti-HIV-1 activity did inhibit reverse transcriptase; their IC50 values (concentration required for 50% inhibition) of 20--40 μM were several times higher than their EC50 (effective concentration required for 50% inhibition) for the cytopathic effect of HIV-1 in MT-4 cell culture ([@b105-btt-1-151]). Twelve isatin derivatives of this series were also active against hepatitis C virus (HCV) RNA replication showing 80% inhibition at 50 μg/ml, however, biological targets responsible for this effect have not been investigated ([@b105-btt-1-151]). *N-*methylisatin 3-thiosemicarbazone (methisazone, Marboran) was effective in the prophylaxis of smallpox. In several trials during epidemics, methisazone reduced the attack rate by 75 to 95% ([@b24-btt-1-151]). Isatin 3-thiosemicarbazone inhibited vaccina virus multiplication in chicken embryo kidney cells or HeLa cells with IC~50~ value \<1 μg/ml, but in the case of other viruses (monkeypox virus and variola virus) the IC~50~ values were higher (30--60 μg/ml). Mechanism of action of isatin 3-thiosemicarbazone remains to be clarified, certain evidence exists that it influences with viral maturation ([@b24-btt-1-151]).

1 μM N-methyl isatin β-thiosemicarbazone (Me-IBT) inhibited Rous sarcoma virus RNA-dependent DNA polymerase by 50%, whereas in combination with 1 μM CuSO~4~, which caused minor (10%--15%) inhibition, it caused nearly total inhibition of the enzyme activity ([@b60-btt-1-151]).

The isatin analogues, 5-Fluoroisatin, 5-Chloroisatin, 6-Chloroisatin, 7-Chloroisatin, and 5-methylisatin, but not 4-Bromoisatin and 5-Iodoisatin inhibited production of nitric oxide and PGE2 TNF-α by RAW 264.7 macrophage cells activated by a mixture of lipopolysaccharide (LPS) and interferon γ ([@b70-btt-1-151]). However, their effectiveness insignificantly differed from the effect of isatin. As in the case of isatin the inhibition of NO and PGE2 production in LPS-INF-γ is obviously associated with the isatin effect on expression of inducible nitric oxide synthase and cyclooxygenase-2 respectively, as it has been demonstrated by a Western blot analysis ([@b70-btt-1-151]). Production of TNF-α by the activated cells was decreased by the all isatins studied, and 5-iodoisatin exhibited the highest effectiveness ([@b70-btt-1-151]). The authors suggest that isatin and its analogues may have chemopreventive activity against the malignant process by down-regulating COX-2 and/or iNOS ([@b70-btt-1-151]).

Carboxylesterases are ubiquitous enzymes involved into metabolism of various xenobiotics including drugs employed clinically (eg, demerol, lidocaine, capecitabine) ([@b62-btt-1-151]; [@b42-btt-1-151]). Isatin analogues containing hydrophobic groups attached at a variety of positions within these molecules, exhibited potent and specific inhibition of carboxylesterases with Ki values in the nM range ([@b42-btt-1-151]). Authors believe that isatin analogues may be considered as the lead compounds for the development of inhibitors modulating drug metabolism in vivo.

Interaction of isatin with its analogues and drugs
--------------------------------------------------

Although the interaction between isatin and its analogues, and drugs at specific biological targets still requires detailed analysis, there is evidence that isatin protects MAO B against irreversible inhibiton by mechanism based inhibitors phenelzine ([@b88-btt-1-151]) and pargyline (Medvedev et al unpublished observation). Deprenyl in its turn inhibited isatin binding to GAPDH and this effect was rather specific because the other mechanism based MAO inhibitor, tranylcypromine, was ineffective ([@b75-btt-1-151]). Deprenyl was somewhat more effective in inhibition of RNase activity of GAPDH than isatin, and during their combined addition the effect of RNase inhibition was somewhat less pronounced than in the case of independent action of deprenyl ([@b75-btt-1-151]). Thus it is possible that being less effective than the pharmacological drug, deprenyl, isatin may attenuate some of its effects.

5-Hydroxyisatin and to a lesser extent N-methylisatin inhibited ubiquitin binding to aminoisatin immobilized onto a cuvette of optical biosensor Biacore (Buneeva et al in preparation). The latter suggests that endogenous isatin may attenuate interaction of some biological targets with drugs containing isatin moiety and therefore influence expected therapeutic effect.

Conclusions
===========

Isatin and its analogues act on a large number of biological targets and have a wide variety of actual and potential pharmacological actions. There is some evidence that isatin may attenuate the effects of certain pharmaceutical agents on specific biological targets, such as monoamine oxidase inhibitors and/or neuroprotective drugs ([@b88-btt-1-151]; [@b75-btt-1-151]). Isatin can be present in blood in the micromolar range and increases in response to stress ([@b46-btt-1-151]). This suggests that endogenous isatin, and possibly its precursors and metabolites, may affect the sensitivity of biological targets to therapeutics employed a range of diseases and disorders.

The studies discussed here were supported by grants from The Welcome trust (072381/Z/03), Royal Society, INTAS, and Russian Foundation for Basic Research (No 00-04-48446, 03-04-48244, 06-04-48355, 07-04-00803).
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###### 

Concentrations of isatin in brain and some other tissues of the rat

  Tissue             Range of isatin concentrations, μM
  ------------------ ------------------------------------------------------
  Whole brain        0.3--0.4
  Hippocampus        0.9--1.3
  Cerebellum         0.8--1.2
  Striatum           0.6--1.0
  Heart              0.79--2.62
  Liver              0.77--1.45
  Kidney             0.88--1.32
  Lung               0.14--1.20
  Spleen             0.35--0.62
  Testes             0.16--0.63
  Seminal vesicles   2.37--47.4[\*](#tfn2-btt-1-151){ref-type="table-fn"}
  Vas deferens       1.58--79.0[\*](#tfn2-btt-1-151){ref-type="table-fn"}

Calculations have been made using data on tissue isatin content ([@b122-btt-1-151]; see also [@b77-btt-1-151]) and water content in various tissues of the rat ([@b96-btt-1-151]).

Due to lack of data available on water content in vas deferens and seminal vesicles isatin concentrations have been calculated using data on water content in testes (0.861 ml/g) ([@b96-btt-1-151]).

###### 

Molecular targets sensitive to physiological concentrations of isatin (modified from [@b34-btt-1-151]; [@b78-btt-1-151])

  --------------------------------------- ---------------------------------------------------------------------- -------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Inhibition ≥50% caused by 1 μM isatin   Inhibition ≥50% caused by 10 μM isatin                                 Inhibition 20%--40% caused by 10 μM isatin                           Inhibition \<20% caused by 10 μM isatin

  *Receptor binding:*\                    *Enzyme activity:*\                                                    *Neurotransmitter receptor binding:*\                                *Neurotransmitter receptor binding:*\
  \[^121^I\]ANP- receptor binding         Natriuretic peptide receptor (NPR-A) coupled guanylate cyclase MAO B   NMDA receptor AMPA receptor\                                         Adenosine-1, adenosine-2; α *-*1 , α*-2,* β*-*adrenergic; dopamine-1, dopamine-2; GABA A, GABA B; histamine-I, histamine-2, histamine-3; 5-HT-1, S-HT-2, 5-HT-3; muscarinic-1, muscarinic-3; nicotinic; kainic acid; glycine (strychnine insensitive); opiate (σ, μ, κ).
                                                                                                                 Dopamine D4-receptor\                                                
                                                                                                                 Muscarinic (M-2) receptor\                                           
                                                                                                                 Glycine (strychnine sensitive) receptor                              

  *Enzyme activity:*\                                                                                            *Growth factor receptor binding:* Epidermal growth factor receptor   *Brain and gut peptides and growth factor receptor binding:*\
  NO-stimulated guanylate cyclase                                                                                                                                                     Angiotensin II, type 2; vasopressin-I; bombesin; endothelin B; substance P; CCK~A~; CCK~B~ neuropeptide Y; neurotensin; somatostatin; vasoactive intestinal peptide; nerve growth factor, NPR-C

                                                                                                                 *Ion channel binding:*\                                              *Ion channel binding:* Chloride; sodium; potassium; calcium *Uptake site binding:* Adenosine; choline; dopamine; GABA; noradrenaline; 5-HT.\
                                                                                                                 Potassium channel\                                                   *Other targets:* Forskolin; leukotriene B4, leukotriene D4; thromboxane A2, ERK
                                                                                                                 *Other targets*:\                                                    
                                                                                                                 Inositol triphosphate Protein kinase C\                              
                                                                                                                 *Enzyme activity:*\                                                  
                                                                                                                 MAO A                                                                
  --------------------------------------- ---------------------------------------------------------------------- -------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
